Libra Infusions Limited

DSE:LIBRAINFU Stock Report

Market Cap: ৳1.7b

Libra Infusions Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Libra Infusions's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth11.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2019

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Libra Infusions makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DSE:LIBRAINFU Revenue, expenses and earnings (BDT Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 191972560
30 Jun 181916610
31 Mar 18191-16600
31 Dec 172415620
30 Sep 172455620
30 Jun 172446630
31 Mar 172905670
31 Dec 162593630
30 Sep 162318600
30 Jun 162386570
31 Mar 162329620
31 Dec 152476610
30 Sep 15272-4590
30 Jun 152874590
30 Jun 142827550
30 Jun 132275450

Quality Earnings: Insufficient data to determine if LIBRAINFU has high quality earnings.

Growing Profit Margin: Insufficient data to determine if LIBRAINFU's profit margins have improved over the past year.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if LIBRAINFU's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare LIBRAINFU's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if LIBRAINFU's earnings growth over the past year exceeded the Pharmaceuticals industry average.


Return on Equity

High ROE: LIBRAINFU has a negative Return on Equity (0%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.